Pandorum Technologies, a biotechnology firm specializing in programmable regenerative medicine, has successfully closed an $18 million Series B funding round. This significant capital infusion, led by Protons Corporate, is earmarked to accelerate the clinical development of its innovative exosome-based therapies. The funding will also fuel the company's strategic global expansion across the United States, Asia, and the Middle East.
Strategic Investment for Global Growth
The financing round saw participation from a diverse group of investors, including Galentic Pharma, marquee investor Ashish Kacholia, and the Burman Family. Guided by advisor Bandana Kankani, the investment was structured to optimize value creation and support the company's ambitious roadmap. This capital is pivotal for advancing clinical trials, scaling manufacturing capabilities, and establishing a robust international market presence.
A Novel Approach to Tissue Regeneration
At its core, Pandorum's proprietary platform integrates biology, engineering, and computation to create tunable regenerative therapies. These exosome-based treatments are designed to reprogram damaged tissues affected by inflammation and fibrosis, guiding them toward functional recovery. This method represents a significant shift from conventional treatment paradigms by targeting the underlying biological processes of disease.
Co-founder and CEO Dr. Tuhin Bhowmick described the company's philosophy as restoring the body's "biological memory," much like repairing the Ship of Theseus. This approach views tissue health and degeneration as a navigational challenge within a complex biological landscape. The goal is to develop therapies that can intelligently guide the body's natural regenerative capabilities.
Targeting Corneal Blindness with Kuragenx
The company's lead therapeutic candidate, Kuragenx, is focused on treating severe ocular surface diseases like Stevens–Johnson Syndrome and Neurotrophic Keratitis. In a major validation of its potential, Kuragenx has received Orphan Drug Designation from the U.S. Food and Drug Administration. This designation highlights the urgent need for new treatments for these rare but debilitating conditions.
Establishing a Global Clinical and Manufacturing Footprint
To support its global ambitions, Pandorum has established a distributed manufacturing network through strategic partnerships. The company is collaborating with AGC Biologics in Italy to supply the U.S. and European markets and with Nucelion Therapeutics in India for the Asia-Pacific region. This framework is designed to ensure a reliable and scalable supply of its therapies worldwide.
The clinical translation of Pandorum's science is being spearheaded by a team of world-renowned clinicians in New Delhi, Kyoto, and Chicago. These collaborations are essential for navigating the complexities of international clinical trials and ensuring the therapies meet global standards. This network of experts provides critical validation and guidance for the company's development programs.
Expanding the Therapeutic Pipeline
While ophthalmology is the initial focus, Pandorum intends to apply its versatile platform to a broader range of systemic conditions. The company is actively exploring therapies for inflammatory and degenerative diseases that affect the lung, liver, and nervous systems. This long-term vision aims to address a wide spectrum of unmet medical needs through regenerative medicine.
This $18 million financing marks a pivotal moment for Pandorum Technologies, providing the necessary resources to transition its breakthrough science into clinical reality. The investment validates the company's innovative approach to regenerative medicine and strengthens its position to deliver disease-modifying therapies to patients globally. With a clear strategy for clinical development and international expansion, Pandorum is poised to make a significant impact.